drugset

drugset / Trial / NCT07195916

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT07195916 ↗

Phase 1 Recruiting 280 enrolled Incyte Corporation

Non-randomizedSequentialOpen-labelTreatment

Summary

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Timeline

Start: 2026-01-08
Primary completion: 2028-08-18
Completion: 2028-08-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCA036873	Unknown	—	Intravenous

Indications